The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tuberculosis therapy: past, present and future
Open accessAbstract
The major historical landmarks of tuberculosis (TB) therapy include: the discovery of effective medications (streptomycin and para-aminosalicylic acid) in 1944; the revelation of “triple therapy” (streptomycin, para-aminosalicylic acid and isoniazid) in 1952, which assured cure; recognition in the 1970s that isoniazid and rifampin could reduce the duration of treatment from 18 to 9 months; and the observation in the 1980s that adding pyrazinamide to these drugs allowed cures in only 6 months. To combat noncompliance, intermittent regimens, twice or thrice weekly, have been proven to cure even far-advanced TB in as few as 62–78 encounters over 26 weeks. However, these regimens are not sufficiently short or convenient to facilitate effective treatment in resource-poor countries. Therefore, drug-resistant strains have emerged to threaten TB control in various areas of the world, including India, China, Russia and the former Soviet Union. For these reasons, it is vital that new medications are developed to shorten the duration of therapy, increase the dosing interval of intermittent regimens and replace agents lost to resistance. Other special considerations include identifying optimal therapy for persons with acquired immune deficiency syndrome, particularly noting the problems of drug/drug interactions for those receiving antiretroviral treatment. Finally, the Alchemist's Dream of tuberculosis should be pursued: modulating the immune response to shorten treatment and/or overcome drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paradoxical Worsening of Tuberculosis in HIV-Infected Persons
Wendel, K. A., Alwood, K. S., Gachuhi, R., Chaisson, R. E., Bishai, W. R., & Sterling, T. R. (2001) · Chest · doi:10.1378/chest.120.1.193 · Cited by 157
Cited by
Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis
Chan, E. D., Laurel, V., Strand, M. J., Chan, J. F., Huynh, M.-L. N., Goble, M., & Iseman, M. D. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200308-1159oc · Cited by 336
Self-citationCohen, K. A., Abeel, T., Manson McGuire, A., Desjardins, C. A., Munsamy, V., Shea, T. P., Walker, B. J., Bantubani, N., Almeida, D. V., Alvarado, L., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001880 · Cited by 274
New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development
van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., & Aarnoutse, R. E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00749-08 · Cited by 257
Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting
Nimje, N., Agarwal, A., Saraogi, G. K., Lariya, N., Rai, G., Agrawal, H., & Agrawal, G. P. (2009) · Journal of Drug Targeting · doi:10.3109/10611860903115308 · Cited by 137
Metadata
- Authors
- Iseman, M. D.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2002-07-01
- Volume
- 20
- Issue
- 36 suppl
- Pages
- 87S-94s
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2118758782
- Cited by
- 207
- References
- 1
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tuberculosis therapy: past, present and future. https://app.cochat.ai/papers/10.1183/09031936.02.00309102
- The paper
- Iseman, M. D. (2002). Tuberculosis therapy: past, present and future. European Respiratory Journal. https://doi.org/10.1183/09031936.02.00309102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.